Cibc World Market Inc. Reduces Stock Holdings in Abbott Laboratories $ABT

Cibc World Market Inc. lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 28.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 364,776 shares of the healthcare product maker’s stock after selling 146,690 shares during the quarter. Cibc World Market Inc.’s holdings in Abbott Laboratories were worth $48,858,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in ABT. Norges Bank bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at $3,026,180,000. Laurel Wealth Advisors LLC grew its holdings in Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock valued at $823,804,000 after purchasing an additional 6,011,891 shares during the period. Vanguard Group Inc. increased its position in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Abbott Laboratories by 180.7% in the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock worth $416,659,000 after buying an additional 1,972,097 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Abbott Laboratories by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after buying an additional 1,390,554 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ABT. Citigroup dropped their price target on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Sanford C. Bernstein dropped their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Barclays decreased their price target on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday, February 2nd. Daiwa Securities Group dropped their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Finally, Argus cut their target price on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $137.05.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $113.66 on Thursday. The firm has a market cap of $197.64 billion, a PE ratio of 30.55, a PEG ratio of 1.79 and a beta of 0.75. The stock has a 50 day moving average of $120.01 and a 200 day moving average of $126.61. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the prior year, the firm earned $1.34 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be issued a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. Abbott Laboratories’s payout ratio is presently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.